FMP
NASDAQ
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
1.52 USD
-0.03 (-1.97%)
Valuation Date:
May 3, 2024 4:00 PM
Share Price on Valuation Date
$1.52
Stock Beta
-3.147
Shares Outstanding
33236049